Title
Category
Credits
Event date
Cost
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Siddharth Sheth, DO, MPH, will provide a brief overview of clinical factors relevant to head and neck cancers and basic management. Themain focus will be the current use of technologies that aid with the diagnosis, treatment selection, and monitoring of patientswith head and neck cancers. This includes next generation sequencing assays for DNA sequencing, RNA sequencing, andcirculating tumor DNA. The goal of the presentation is for providers to be comfortable with ordering and basic interpretation ofthese tests.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Marc Bjurlin, DO, MSc, FACOS, gives a contemporary overview of prostate cancer screening with a focus on prostate cancer in men in North Carolina.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.25 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Hung-Jui Tan, MD, MSHPM, will review recent practice-changing research and new management recommendations for patients with prostate, kidney, bladder, and testicular cancer.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Mark Woodcock gives a broad overview of the multidisciplinary approaches for the treatment of soft tissue sarcomas in adults, and detailed updates in management with systemic therapies. Specific attention is paid to sarcoma sub-types which may warrant special considerations.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 ASRT
  • 1.00 CTR Category A
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Natalie Grover, MD, will review some of the recent advances in the treatment of lymphoma, including the incorporation of novel targeted agents in the frontline treatment of diffuse large B cell lymphoma and Hodgkin lymphoma, the use of CAR-T cell therapy in second-line treatment in diffuse large B cell lymphoma, and recently approved drugs by the FDA for lymphoma.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ASRT
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Katherine Garman, MD, and Meira Epplein, PhD, will provide information on gastric cancer and important risk factors such as H. pylori infection. We will describe some of the racial disparities associated with gastric cancer in the US, highlighting those that are relevant for North Carolina. We will also discuss H. pylori as a modifiable risk factor and we will review current guidelines on H. pylori testing, treatment, eradication testing, and the growing problem of antibiotic resistance.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Daniel Richardson, MD, MA, MSc, will explore best practices to approach the care of older adults with leukemia. He will also discuss novel therapeutic options for patients with acute lymphoblastic and acute myeloid leukemia alongside practical considerations to approach shared decision-making.
  • Patient Centered Care
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Introduction and discussion of supportive care programs in a "home away from home" for patients during their cancer journey.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.50 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Frances Collichio, MD, reviews the common and uncommon side effects of immune check point inhibitors. She also discusses the relatively new concept of delayed immune related events.
  • Research to Practice
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Tech
  • 1.00 AMA PRA Category 1 Credit
  • 1.25 ASRT
  • 1.00 CTR
  • 1.00 NCPD/CNE
  • 1.00 Participation
$0.00
Dominique Higgins, MD, PhD, provides an overview of diagnostic criteria for primary CNS brain tumors, and the current approved and investigational treatments that are available and on the horizon.

Pages